

Adult Headache Pathway

- Do you have a headache all the time or does it come & go? (Tension Type Headache or Medicines Overuse Headache usually have pain all the time)
 - If intermittent what do you do when you have the pain? (patients with migraine want to lie/sit still when pain is bad, those with cluster headaches can't sit still when having an attack)
 - what tablets are you taking now and have you taken before?

Patient presents with headache

Take history & examine including BP, temporal arteries (if age > 50years) & fundoscopy

Exclude red flags

Secondary headache - non serious cause

Posterior headaches often relate to cervicogenic headaches

 Unlikely to be sinuses, TMJ dysfunction or teeth unless other signs /symptoms indicative of this

 Consider medication – esp combined oral contraceptive pill (OCP). If patient has migraines with aura then OCP is contraindicated

 Consider facial pain trigeminal neuralgia as a cause of 'headache'

Red Flags - Headache that is new or unexpected in an individual patient

- Thunderclap headache (intense headache of "explosive" onset suggest SAH)
- Jaw claudication (suggests temporal arteritis - take ESR /CRP & start steroids immediately)
- Headache with atypical aura (duration >1 hour, or including significant / prolonged motor weakness)
- Headache associated with postural change (bending) or coughing (possible raised ICP)
- New onset headache in patient with history of cancer, especially if < 20 years
- Unilateral red eye – consider angle closure glaucoma
- Remember carbon monoxide poisoning (also causes lethargy + nausea)
- Rapid progression of sub-acute focal neurological deficit*
- Rapid progression of unexplained cognitive impairment / behavioural disturbance*
- Rapid progression of personality changes confirmed by witness where there is no reasonable explanation*
- New onset headache in a patient with a history of HIV / immunosuppression*
- New onset headache in a patient older than 50 years *
- Headache causing patients to wake from sleep*
- Progressive headache, worsening over weeks or longer*

Primary headache
 The major types are listed below – it is important to realise however that patients may have more than one type, so can develop tension type headaches on underlying migraine, or medication overuse with tension type headaches
 NICE recommends keeping a headache diary

Most people who attend their GP with recurrent / chronic headaches have migraine.

 A recurrent severe headache associated with nausea and photophobia is 98% predictive of migraine

Consider admission, urgent MRI scan (marked *) or 2ww referral as appropriate (direct access MRI not available in all CCGs)

Migraine without aura

Migraine with aura

Tension type headache (TTH)

Medication Overuse Headache (MOH)

Cluster headache

Diagnostic criteria - at least 5 attacks fulfilling criteria 1-4
 1) Lasts 4-72 hours untreated
 2) At least 2 of the following
 Unilateral location
 Pulsating quality
 Moderate/severe pain
 3) Nausea / vomiting and/or photophobia
 4) No other cause identified
Chronic migraine with or without aura occurring everyday needs specialist review

Occurs in 1/3 of migraine sufferers
 Aura 5-60 minutes prior to headache
 Usually visual – note blurring & spots not diagnostic
Chronic migraine with or without aura occurring everyday needs specialist review


Usually episodic
 Deemed chronic if >15days per month
 Stress is common trigger but not always obvious

 Can occur in combination with migraine and secondary headache triggers especially cervicogenic /neck problems

M:F (1:5 ratio)
Medication history is crucial especially use of over the counter analgesia

 Can occur with other headache types
 Prophylaxis medication doesn't help & can worsen

Affects M:F (3:1 ratio)
 Usually aged 20+ years
 Bouts last 6-12 weeks.
 Usually occur 1-2x year, often at same time of year.
 Rarely chronic throughout year.
 Very severe – often at night & lasts 30-60 minutes
 Strictly unilateral
 Ipsilateral conjunctival injection, rhinorrhea +/- Ptosis confirm



Adult Headache Guideline

Nottingham and Nottinghamshire Adult Chronic Headache Pathway With Open Access to MRI Scanning

The following information is to support prescribers regarding the medicines aspects of the pathway, please refer to the BNF or Summary of Product Characteristics for further information on contraindications, precautions, adverse effects and interactions.

These guidelines have been developed using both British Association for the Study of Headache (BASH 2010) and NICE Headache (2012) guidelines.

Treatment of acute migraine

A stepped approach is often recommended commencing as early as possible with an analgesic and anti-emetics/pro-kinetic if required, and escalating to a 5HT₁ receptor agonist (triptan) if this approach fails.

Aspirin or ibuprofen with or without paracetamol	Need to establish therapeutic levels quickly aspirin 600-900mg or ibuprofen 400-600mg paracetamol 1g
Metoclopramide or domperidone	metoclopramide 10mg or domperidone 20 mg
Aspirin plus metoclopramide	Aspirin 900mg plus Metocolopramide 10mg
Paracetamol plus metoclopramide	Paracetamol 500mg plus Metoclopramide 5mg
Domperidone and Diclofenac suppositories	Domperidone 30mg Diclofenac 50mg or 100mg – see notes below

Notes:

1. Please be aware of recent MHRA guidance on the use of anti-emetics and diclofenac. Links to the guidance is available through www.nottinghamshireformulary.nhs.uk
2. Drugs should be given as soon as the onset of an attack is recognised.
3. The addition of a gastric motility agent will aid gastric emptying, as well as relieving nausea.
4. Anti-migraine drugs containing Metoclopramide are not suitable for patients under the age of 20 years.
5. Since peristalsis is often reduced in migraine attacks, dispersible preparations may be helpful.
6. Suppositories are useful if vomiting or severe nausea present.

Adult Headache Guideline

Triptans (5HT₁-receptor agonists)

Please see Nottinghamshire Formulary at www.nottinghamshireformulary.nhs.uk for further drug information. Try using the most cost-effective preparation first line, current Nottinghamshire formulary triptans are listed below.

Quicker onset of action, shorter half life		Slower onset of action. Longer half life. Lower incidence of side effects and may be useful where recurrence is a problem	
Sumatriptan (first line)	Tablets 50, 100mg Injection 6mg per 0.5ml Nasal spray 10mg or 20mg per 0.1ml/dose	Naratriptan	Tablet 2.5mg
Zolmitriptan	Tablets 2.5mg or Melts 2.5, 5mg Nasal spray 5mg per 0.1ml/dose	Frovatriptan	Tablet 2.5mg

Notes:

1. NICE recommends that oral triptans should be used first line and other preparations only considered if these are ineffective or not tolerated.
2. A second Triptan should not be taken if the first dose is ineffective.
3. Triptans are contraindicated in, uncontrolled hypertension, or risk factors for coronary heart disease or cerebral vascular disease.
4. Different Triptans have different profiles of 5HT site action. If the first Triptan tried fails, it is worth trying alternative ones. A pragmatic approach would be to choose the cheapest one from each group as a first line.
5. Wafer formulations obviate the need for water and do not get absorbed in mouth.
6. Nasal spray is useful when vomiting is a problem.

Prevention of migraine

Prophylaxis is used to reduce the number of attacks in circumstances when acute therapy, used appropriately, gives inadequate symptom control. There are no specific guidelines as to when prophylaxis should be commenced. Considerations include frequency, impact, failure of acute therapy, avoidance of medication overuse headache. The potential for teratogenic effects should be noted particularly with anti epileptic medications. In line with NICE recommendations these updated guidelines no longer include a recommendation to use pizotifen. Additionally propranolol is now recommended first line again in line with NICE recommendations and licensed indications.

Notes:

1. Propranolol, metoprolol and timolol are licensed. Atenolol has the advantage of once daily dosing and probably works as well.
2. Start at the lowest dose and build up gradually. Maintain the maximum tolerated dose for a minimum of 6 weeks before assessing. Discuss with patient at 6 months whether a gradual reduction and elimination of prophylactic medication might be considered.
3. Amitriptyline is useful with co-existent tension type headache, disturbed sleep or depression.
4. Note that gabapentin has the potential for abuse and is no longer recommended by NICE for prophylactic treatment of migraine.

Adult Headache Guideline

Topiramate

Topiramate is licensed for migraine prophylaxis in adults, and it is now recommended for use in the NICE headache clinical guideline. Nottinghamshire Area Prescribing Committee has assigned topiramate as Amber 3 in the traffic light guidelines.

The SPC (summary of product characteristics) will have full information on cautions, contra-indications and side effects.

Place in therapy

This will be tailored to each patient, but as highlighted in the headache pathway, it should be considered when

- The frequency of migraines is such that regular prophylaxis is warranted
- A suitable trial of first line prophylactic medication (B blockers and/or amitriptyline) have failed to offer relief of symptoms
- Advise women of childbearing potential that topiramate is associated with a risk of foetal malformations and can impair the effectiveness of hormonal contraception. It is contraindicated in pregnancy and in women of childbearing potential if an effective method of contraception is not used.

Review

Continuing therapy should be reviewed every 6 months.

Dose

Note can take 6-8 weeks before maximum effect gained.

Commence topiramate at 25mg nightly, and increase (see below) if required.

Titration Schedule

The dosage should then be increased in increments of 25 mg/day administered at 1-week intervals. If the patient is unable to tolerate the titration regimen, longer intervals between dose adjustments can be used.

Some patients may experience a benefit at a total daily dose of 50 mg/day. The recommended total daily dose of topiramate as treatment for the prophylaxis of migraine headache is 100 mg/day administered in two divided doses. No extra benefit has been shown from the administration of doses higher than 100 mg/day.

Topiramate Dosage	Morning	Evening
Week 1		25mg
Week 2	25mg	25mg
Week 3	25mg	50mg
Week 4	50mg	50mg

Adult Headache Guideline

Contraindications

Known hypersensitivity
Breast feeding
Pregnancy

Cautions

Avoid abrupt withdrawal
Hepatic impairment
Renal impairment

Topiramate has been associated with acute myopia with secondary angle closure glaucoma, typically occurring within 1 month of starting treatment. Choroidal effusions have also been reported. If raised intraocular pressures occur – seek ophthalmology advice and stop topiramate as rapidly as possible

Side Effects

Nausea, dyspepsia and diarrhoea
Dry mouth and taste disturbance
25% of people experience anorexia/loss of appetite
Drowsiness, insomnia, dizziness
50% of people experience initial paraesthesia (which usually settles)

Rarely - reduced sweating metabolic acidosis and alopecia

Very rarely - leucopenia, thrombocytopenia and serious skin reactions

Interactions

Oestrogens – metabolism accelerated – reduced contraceptive effect
Progestogens – metabolism accelerated – reduced contraceptive effect
Glibenclamide – possibly reduces plasma concentrations
Lithium – possibly affects plasma concentration

Costs (Drug Tariff and BNF November 2016)

Topiramate tablets

25mg x 60 £1.85

50mg x 60 £2.09

Topiramate sprinkle capsules (Topamax[®])

25mg x 60 £22.18

50mg x 60 £36.45

Topiramate tablets are now available generically and should be prescribed in preference to sprinkle capsules due to price difference.

For further information on contraindications, precautions, adverse effects and interactions refer to the BNF or [Summary of Product Characteristics](#).

Adult Headache Guideline

Useful Resources – these guidelines have been developed using NICE and BASH guidelines below

- 1) NICE 2012 Headaches – Diagnosis and management of headaches in young people and adults. Clinical guideline 150
- 2) The British Association for the Study of Headache (BASH) are the main source of these guidelines, and they have more information at www.bash.org.uk/
- 3) Migraine in Primary Care Advisors is another useful web sit with guidance and information on further education www.mipca.org.uk/
- 4) The International Headache Society <http://ihs-classification.org/en/>

Self Help Resources

Patient UK – www.patient.co.uk

Migraine Action association <http://www.migraine.org.uk/>

Migraine Trust - <http://www.migrainetrust.org/>

Organization for the understanding of cluster headaches - <http://www.ouchuk.org>

NHS Choices <http://www.nhs.uk/conditions/Headache/Pages/Introduction.aspx>

About this Guideline

Original Authors & contributors in alphabetical order

Nikos Evangelou – consultant neurologist NUH
Rob Lenthall – consultant neuro-radiologist NUH
Alastair McLachlan – GP and clinical lead for NORCOMM
Tony Marsh – GP clinical Lead for NNE
Hugh Porter –GP and clinical lead for UNICOM
Guy Sawle consultant neurologist NUH
Adrian Wills – consultant neurologist NUH

Reviewed and updated 2016

Tanya Behrendt, Hugh Porter, Nikos Evangelou and Roger Knaggs in consultation with Nottinghamshire APC and member organisations.